Atea Pharmaceuticals (AVIR) Non-Current Assets (2019 - 2026)

Atea Pharmaceuticals' Non-Current Assets history runs 8 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• In Q1 2026, Non-Current Assets fell 38.0% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $20.9 million (up 25.83% YoY), while the FY2025 annual figure was $4.2 million, up 82.75% from the prior year.
• Non-Current Assets was $3.9 million for Q1 2026 at Atea Pharmaceuticals, down from $4.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q3 2025 to a low of $2.3 million in Q4 2024.
• Historically, Non-Current Assets has averaged $4.8 million across 5 years, with a median of $4.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 1083.23% in 2022, then tumbled 48.75% in 2024.
• A 5-year view of Non-Current Assets shows it stood at $5.8 million in 2022, then fell by 22.0% to $4.5 million in 2023, then sank by 48.75% to $2.3 million in 2024, then soared by 82.75% to $4.2 million in 2025, then declined by 8.23% to $3.9 million in 2026.
• The last three Non-Current Assets figures came in at $3.9 million (Q1 2026), $4.2 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.